The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in ...
Newsable Asianet News on MSN23h
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback